Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.
The company went public through an IPO on May 19, 1992.
The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.
Technology and Procedure Animation
IC-434111-AA OCT2016
published: 24 Feb 2020
Boston Scientific - How SCS Works
In this animated overview, you’ll discover how Spinal Cord Stimulation (SCS) works and how it can help people manage their chronic pain.
NM 932306 AA
published: 24 Feb 2022
Prosthetic Urology: Our Manufacturing Journey
Innovations drive health care advances. As the proven leader in prosthetic urology, Boston Scientific is committed to investing in new technologies, new thinking and new ways to deliver continuous innovation in erectile restoration and male stress urinary incontinence therapies, across the globe. For more information click here: https://bit.ly/prosthetic-urology
published: 16 Apr 2020
Boston Scientific - SCS Patient Educational Video
SCS Patient Educational Video Top 5 Questions NM 507208
published: 20 Nov 2018
EXCELLENCE STORY BOSTON SCIENTIFIC – ITALY
Customer case study CHG-MERIDIAN ITALIA in cooperation with customer BOSTON SCIENTIFIC
published: 02 Aug 2022
Boston Scientific Corporate Video
published: 10 Jun 2013
Boston Scientific Vercise Genus Deep Brain Stimulation System
Introducing the Vercise Genus Deep Brain Stimulation (DBS) System by Boston Scientific.
Every person is unique, so we created a DBS system that’s uniquely customizable for every patient. Vercise Genus offers single and dual channel, rechargeable and non-rechargeable, implantable pulse generators, powered by Cartesia 3D.
Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system. Featuring an MR conditional portfolio and wireless Bluetooth® connectivity, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
For additional information please visit:
http://www.BostonScientific.com/DBS
For US indications visit:
http://www.bostonscientific.com/genus-indications
Innovations drive health care advances. As the proven leader in prosthetic urology, Boston Scientific is committed to investing in new technologies, new thinkin...
Innovations drive health care advances. As the proven leader in prosthetic urology, Boston Scientific is committed to investing in new technologies, new thinking and new ways to deliver continuous innovation in erectile restoration and male stress urinary incontinence therapies, across the globe. For more information click here: https://bit.ly/prosthetic-urology
Innovations drive health care advances. As the proven leader in prosthetic urology, Boston Scientific is committed to investing in new technologies, new thinking and new ways to deliver continuous innovation in erectile restoration and male stress urinary incontinence therapies, across the globe. For more information click here: https://bit.ly/prosthetic-urology
Introducing the Vercise Genus Deep Brain Stimulation (DBS) System by Boston Scientific.
Every person is unique, so we created a DBS system that’s uniquely cust...
Introducing the Vercise Genus Deep Brain Stimulation (DBS) System by Boston Scientific.
Every person is unique, so we created a DBS system that’s uniquely customizable for every patient. Vercise Genus offers single and dual channel, rechargeable and non-rechargeable, implantable pulse generators, powered by Cartesia 3D.
Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system. Featuring an MR conditional portfolio and wireless Bluetooth® connectivity, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
For additional information please visit:
http://www.BostonScientific.com/DBS
For US indications visit:
http://www.bostonscientific.com/genus-indications
Introducing the Vercise Genus Deep Brain Stimulation (DBS) System by Boston Scientific.
Every person is unique, so we created a DBS system that’s uniquely customizable for every patient. Vercise Genus offers single and dual channel, rechargeable and non-rechargeable, implantable pulse generators, powered by Cartesia 3D.
Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system. Featuring an MR conditional portfolio and wireless Bluetooth® connectivity, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
For additional information please visit:
http://www.BostonScientific.com/DBS
For US indications visit:
http://www.bostonscientific.com/genus-indications
Innovations drive health care advances. As the proven leader in prosthetic urology, Boston Scientific is committed to investing in new technologies, new thinking and new ways to deliver continuous innovation in erectile restoration and male stress urinary incontinence therapies, across the globe. For more information click here: https://bit.ly/prosthetic-urology
Introducing the Vercise Genus Deep Brain Stimulation (DBS) System by Boston Scientific.
Every person is unique, so we created a DBS system that’s uniquely customizable for every patient. Vercise Genus offers single and dual channel, rechargeable and non-rechargeable, implantable pulse generators, powered by Cartesia 3D.
Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system. Featuring an MR conditional portfolio and wireless Bluetooth® connectivity, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
For additional information please visit:
http://www.BostonScientific.com/DBS
For US indications visit:
http://www.bostonscientific.com/genus-indications
Boston Scientific was formed June 29, 1979 as a holding company for a medical products company called Medi-Tech, and to position the company for growth in interventional medicine.
The company went public through an IPO on May 19, 1992.
The Taxus Stent was approved in 2003 in Europe and other countries and approved in the United States by the FDA in March 2004. It was the second drug-eluting stent approved in the United States.
See Instruction 1(b) ... 0.5 ... 2 ... BOSTON SCIENTIFIC CORP [BSX] 5 ... 300 BOSTON SCIENTIFIC WAY 3 ... 300 BOSTON SCIENTIFIC WAY ... Boston Scientific Corporation published this content on November 13, 2024, and is solely responsible for the information contained herein.
"SkyQuest Technology" ... Several significant factors are expected to promote the growth of the global surgical sutures market ... A ... B ... C ... D ... Aspide Medical EndoEvolution, LLCBoston Scientific CorporationB.Braun Melsungen AG Internacional Farmaceutica ... Mr ... ....
This includes a study to evaluate LockeT in patients that require large-bore venous access such as those used with the Micra pacemakers from Medtronic, the Watchman devices from Boston Scientific, and ...
I met with senior executives at Boston Scientific’s principal manufacturing facility in Owen County, which seeks innovators and natural problem-solvers to help advance the newest and most effective ...
This week’s tour of the Boston life sciences ecosystem includes stops at startups like Seaport Therapeutics and Ring Therapeutics, as well as medical device giant Boston Scientific ... .
On November 7, 2024, Boston Scientific Corporation (the "Company") announced that it is resuming the AVANT GUARD clinical trial studying a new population of drug-naïve patients with persistent atrial fibrillation.